The purpose of this study is to compare asenapine with placebo in the treatment of depression
associated with bipolar disorder, type I over eight weeks.
We hypothesize that patients will show significantly greater improvement with asenapine than
placebo over eight weeks of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
University of Cincinnati
Collaborators:
Merck Sharp & Dohme Corp. University of Louisville